https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-positive-results-from-pivotal-phase-3-trial-allele-of
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-preliminary-results-for-ata2271-a-next-generation
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11
https://www.nasdaq.com/press-release/european-medicines-agency-ema-validates-atara-biotherapeutics-marketing-authorization
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-at-three-upcoming-investor-conferences-2021-11
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-eight-abstracts-at-the-63rd-american-society-of
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-third-quarter-2021-financial-results-and-operational
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-third-quarter-2021-financial-results-on-thursday
https://www.nasdaq.com/press-release/atara-biotherapeutics-presents-new-magnetization-transfer-ratio-imaging-data-and-two
https://www.nasdaq.com/press-release/atara-biotherapeutics-and-pierre-fabre-enter-strategic-collaboration-to-commercialize
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-9
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-phase-1-study-update-of-ata188-in-progressive
https://www.nasdaq.com/press-release/european-medicines-agency-grants-atara-biotherapeutics-accelerated-assessment-of-tab
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-8
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-in-a-panel-discussion-at-the-citi-16th-annual
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-second-quarter-2021-financial-results-and-operational
https://www.nasdaq.com/press-release/atara-biotherapeutics-appoints-cell-therapy-and-oncology-commercialization-veteran
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-second-quarter-2021-financial-results-on-monday
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6
https://www.nasdaq.com/press-release/atara-biotherapeutics-joins-the-rare-disease-company-coalition-alongside-industry
https://www.nasdaq.com/press-release/atara-biotherapeutics-presents-positive-tab-celr-long-term-overall-survival-data-for
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-at-the-cowen-virtual-oncology-innovation-summit
https://www.nasdaq.com/press-release/atara-biotherapeutics-names-cell-therapy-oncology-leader-cokey-nguyen-ph.d.-as-chief
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-first-quarter-2021-financial-results-and-operational
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-first-quarter-2021-financial-results-on-tuesday-may
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2
https://www.nasdaq.com/press-release/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-in-virtual-33rd-annual-roth-conference-2021-03
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/atara-biotherapeutics-presents-key-data-for-advancing-the-development-of-tab-celr-and
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-data-at-the-2021-transplantation-cellular-therapy
https://www.nasdaq.com/press-release/atara-biotherapeutics-will-present-recent-advancements-and-key-upcoming-milestones-at
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/atara-biotherapeutics-provides-regulatory-update-for-tab-celr-for-epstein-barr-virus
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-pricing-of-%24175.0-million-public-offering-2020-12-08
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-proposed-offering-of-common-stock-2020-12-07
https://www.nasdaq.com/press-release/atara-biotherapeutics-presents-first-preclinical-evaluation-of-ata3219-a-next
https://www.nasdaq.com/press-release/bayer-and-atara-biotherapeutics-enter-strategic-collaboration-for-mesothelin-targeted
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences-2020-11-16
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-new-open-label-extension-data-including-15-month
https://www.nasdaq.com/press-release/atara-biotherapeutics-presents-new-preclinical-data-on-ata3271-a-next-generation
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-third-quarter-2020-financial-results-and-operational
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-third-quarter-2020-financial-results-on-monday
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-clinical-data-in-epstein-barr-virus-driven-ebv
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-all-progressive-multiple-sclerosis-patients-with
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-fda-clearance-of-ind-for-ata2271-a-next-generation
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-12-month-data-from-all-four-cohorts-in-the-phase-1a
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-second-quarter-2020-financial-results-and-operational
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-second-quarter-2020-financial-results-on-wednesday
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-full-exercise-of-underwriters-option-to-purchase
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-first-patient-enrolled-in-randomized-placebo
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-its-2020-annual-meeting-of-stockholders-will-be-held
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-at-two-upcoming-conferences-2020-06-04
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-pricing-of-%24175.5-million-public-offering-2020-05-27
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-proposed-offering-of-common-stock-and-pre-funded
https://www.nasdaq.com/press-release/atara-biotherapeutics-presents-data-demonstrating-safety-sustained-disability
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-late-breaking-ata188-data-in-progressive-multiple
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-presentation-of-late-breaking-preclinical-data-on
https://www.nasdaq.com/press-release/atara-biotherapeutics-names-cell-therapy-oncology-leader-jakob-dupont-m.d.-as-global
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-appointment-of-cell-gene-therapy-expert-maria-grazia
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-first-quarter-2020-financial-results-and-operational
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-first-quarter-2020-financial-results-on-wednesday
https://www.nasdaq.com/press-release/atara-biotherapeutics-appoints-biotech-and-finance-industry-veteran-ron-renaud-as-non
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-0
https://www.nasdaq.com/press-release/company-profile-for-atara-biotherapeutics-inc.-2020-04-02
https://www.nasdaq.com/press-release/atara-biotherapeutics-provides-update-in-context-of-covid-19-pandemic-2020-04-02
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences-2020-02-20
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/atara-biotherapeutics-names-kristin-yarema-as-chief-commercial-officer-2020-02-05
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-present-2020-key-milestones-and-progress-in-bringing-off-the
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-participate-at-evercore-isi-second-annual-healthconx
https://www.nasdaq.com/press-release/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent
https://www.nasdaq.com/press-release/atara-biotherapeutics-to-announce-third-quarter-2019-operational-progress-and
